{"id":"W4416019250","doi":"10.1016/j.ijgc.2025.102732","title":"PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"","keywords":"Pembrolizumab; Bevacizumab; Placebo; Paclitaxel; Phases of clinical research; Monoclonal; Ovarian cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001201819,0.0008997829,0.001895859,0.0003316509,0.0002584114,0.0008862486,0.000578472,0.0009181411,0.003428279],"category_scores_gemma":[0.001244938,0.0003785457,0.001877952,0.0003976858,0.0004859181,0.001003618,0.0002756402,0.002713932,0.0006723563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007852116,"about_ca_system_score_gemma":0.0007336029,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001467005,"about_ca_topic_score_gemma":0.003726591,"domain_scores_codex":[0.9996721,0.0001550191,0.0000197911,0.00005934314,0.00002821237,0.00006558371],"domain_scores_gemma":[0.9995108,0.0001488666,0.0001213465,0.00003402496,0.00002046239,0.0001644999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9194792,0.005784591,0.001200645,0.00087754,0.002275753,0.00005084285,0.00006940148,0.0009663919,0.004320254,0.0001388312,0.001411367,0.06342519],"study_design_scores_gemma":[0.8415374,0.1391466,0.01164373,0.0001429675,0.002789578,0.0001052108,0.00007940465,0.0009616296,0.0009755968,0.0003718323,0.002218151,0.00002798301],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839951,0.01032575,0.0003871214,0.0007503805,0.0003454518,0.0006514207,0.0009410321,0.0000791467,0.002524523],"genre_scores_gemma":[0.9890814,0.004782571,0.0006601242,0.0009856748,0.0002501112,0.0005632901,0.00106861,0.00002561378,0.002582706],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003428279,"threshold_uncertainty_score":0.01146877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07765121716790024,"score_gpt":0.4543361136696865,"score_spread":0.3766848965017862,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}